Afrezza denied as experimental or investigational by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Afrezza as Experimental

Afrezza is an FDA-approved inhaled insulin indicated for glycemic control in adults with diabetes. A denial classifying it as experimental or investigational is factually difficult to sustain, given that FDA approval establishes a baseline of safety and efficacy review. However, some insurers apply experimental/investigational language to a drug when their internal coverage policy has not been updated to reflect current clinical practice, or when they interpret "experimental" to mean the drug is not yet established as a preferred or standard treatment within their formulary tier framework. In Afrezza's case, the denial may reflect a coverage policy that predates or does not account for the drug's FDA-approved status and its recognized role in diabetes management.

## Why This Denial Is Appealable

FDA approval is the national standard for determining whether a drug is approved for use. Humana cannot accurately characterize an FDA-approved drug as experimental or investigational for its labeled indication. If the denial rests on this characterization, it is factually incorrect and must be challenged. If Humana's policy instead means that Afrezza is not covered as a preferred product within its formulary — and the experimental label is being used loosely — the appeal should address both the factual basis of the experimental classification and the medical-necessity rationale for coverage as a non-preferred or exception product. Professional society guidelines from the American Diabetes Association (ADA) and the Endocrine Society address inhaled insulin in diabetes management.

## Federal Appeal Rights

• Internal Appeal: File a written appeal with Humana within the deadline on your denial notice. Include documentation of Afrezza's FDA-approved status and your physician's clinical rationale for prescribing it.
• External Review (ACA §2719): Experimental/investigational denials are expressly eligible for external review by an IRO, which assesses the denial against current medical evidence and standards — not the plan's internal policy. File within approximately four months of the adverse benefit determination.
• Expedited Review: Available if your diabetes management would be seriously jeopardized by delay.
• ERISA §503: Employer-plan members have the right to the complete claim file, all criteria used, and a full-and-fair review.

## Documentation to Gather

• Afrezza's FDA approval documentation (NDA approval; publicly available from FDA.gov — your physician can print this)
• Your diabetes diagnosis records, current treatment regimen, and glycemic monitoring history
• Documentation of your experience with prior or current insulin therapy: glycemic outcomes, any adverse effects, and why Afrezza was prescribed
• Your prescribing physician's or endocrinologist's letter explaining the clinical rationale for Afrezza and referencing its FDA-approved status and applicable professional society guidelines
• The exact language in Humana's denial letter classifying Afrezza as experimental, so your appeal can directly address it

## Criteria-Mapping Strategy

This appeal has a factual rebuttal at its core — the drug is FDA-approved — supplemented by a medical-necessity argument for your specific clinical situation.

| Denial Claim | Your Rebuttal | |---|---| | Drug classified as experimental | [FDA approval documentation for Afrezza] | | No established clinical role | [Physician letter citing ADA/Endocrine Society guidance] | | Clinical necessity for this patient | [Treatment history, glycemic data, prescriber rationale] | | Adequate alternative available | [Documentation of why alternatives are not equivalent for you] |

Present the FDA approval documentation first and prominently. An IRO reviewer cannot find a drug experimental when its FDA approval is documented in the record.